192 related articles for article (PubMed ID: 29296081)
21. Modulation of chemoresistance by lysophosphatidic acid (LPA) signaling through LPA
Minami K; Ueda N; Maeda H; Ishimoto K; Otagaki S; Tsujiuchi T
Biochem Biophys Res Commun; 2019 Sep; 517(2):359-363. PubMed ID: 31362892
[TBL] [Abstract][Full Text] [Related]
22. Acid ceramidase expression modulates the sensitivity of A375 melanoma cells to dacarbazine.
Bedia C; Casas J; Andrieu-Abadie N; Fabriàs G; Levade T
J Biol Chem; 2011 Aug; 286(32):28200-9. PubMed ID: 21700700
[TBL] [Abstract][Full Text] [Related]
23. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
Najar HM; Dutz JP
J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
[TBL] [Abstract][Full Text] [Related]
24. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
Hervieu A; Rébé C; Végran F; Chalmin F; Bruchard M; Vabres P; Apetoh L; Ghiringhelli F; Mignot G
J Invest Dermatol; 2013 Feb; 133(2):499-508. PubMed ID: 22951720
[TBL] [Abstract][Full Text] [Related]
25. Silencing of Dicer enhances dacarbazine resistance in melanoma cells by inhibiting ADSL expression.
Yeh YW; Hsu TW; Su YH; Wang CH; Liao PH; Chiu CF; Tseng PC; Chen TM; Lee WR; Tzeng YS
Aging (Albany NY); 2023 Nov; 15(22):12873-12889. PubMed ID: 37976135
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma.
Yang C; Cao H; Liu N; Xu K; Ding M; Mao LJ
Drug Des Devel Ther; 2016; 10():3755-3761. PubMed ID: 27895465
[TBL] [Abstract][Full Text] [Related]
27. Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine.
Singh S; Davis R; Alamanda V; Pireddu R; Pernazza D; Sebti S; Lawrence N; Chellappan S
Mol Cancer Ther; 2010 Dec; 9(12):3330-41. PubMed ID: 21139044
[TBL] [Abstract][Full Text] [Related]
28. Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis.
Valero T; Steele S; Neumüller K; Bracher A; Niederleithner H; Pehamberger H; Petzelbauer P; Loewe R
J Invest Dermatol; 2010 Apr; 130(4):1087-94. PubMed ID: 19940857
[TBL] [Abstract][Full Text] [Related]
29. Metformin pretreatment reduces effect to dacarbazine and suppresses melanoma cell resistance.
Sanches LJ; Marinello PC; da Silva Brito WA; Lopes NMD; Luiz RC; Cecchini R; Cecchini AL
Cell Biol Int; 2022 Jan; 46(1):73-82. PubMed ID: 34506671
[TBL] [Abstract][Full Text] [Related]
30. Imaging G protein-coupled receptors while quantifying their ligand-binding free-energy landscape.
Alsteens D; Pfreundschuh M; Zhang C; Spoerri PM; Coughlin SR; Kobilka BK; Müller DJ
Nat Methods; 2015 Sep; 12(9):845-851. PubMed ID: 26167642
[TBL] [Abstract][Full Text] [Related]
31. Combined Therapy with Dacarbazine and Hyperthermia Induces Cytotoxicity in A375 and MNT-1 Melanoma Cells.
Salvador D; Bastos V; Oliveira H
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408947
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Propper DJ; Braybrooke JP; Levitt NC; O'Byrne K; Christodoulos K; Han C; Talbot DC; Ganesan TS; Harris AL
Br J Cancer; 2000 Jun; 82(11):1759-63. PubMed ID: 10839287
[TBL] [Abstract][Full Text] [Related]
33. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C
Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718
[TBL] [Abstract][Full Text] [Related]
34. Sonodynamic Therapy Using Dacarbazine-Loaded AuSiO
Esmailzadeh A; Shanei A; Attaran N; Hejazi SH; Hemati S
Ultrasound Med Biol; 2022 Jun; 48(6):1131-1142. PubMed ID: 35307236
[TBL] [Abstract][Full Text] [Related]
35. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
Hillner BE; Agarwala S; Middleton MR
J Clin Oncol; 2000 Apr; 18(7):1474-80. PubMed ID: 10735895
[TBL] [Abstract][Full Text] [Related]
36. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
Kiebert GM; Jonas DL; Middleton MR
Cancer Invest; 2003; 21(6):821-9. PubMed ID: 14735685
[TBL] [Abstract][Full Text] [Related]
37. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.
Engesæter B; Engebraaten O; Flørenes VA; Mælandsmo GM
PLoS One; 2012; 7(9):e45492. PubMed ID: 23029050
[TBL] [Abstract][Full Text] [Related]
38. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.
Schadendorf D; Ugurel S; Schuler-Thurner B; Nestle FO; Enk A; Bröcker EB; Grabbe S; Rittgen W; Edler L; Sucker A; Zimpfer-Rechner C; Berger T; Kamarashev J; Burg G; Jonuleit H; Tüttenberg A; Becker JC; Keikavoussi P; Kämpgen E; Schuler G;
Ann Oncol; 2006 Apr; 17(4):563-70. PubMed ID: 16418308
[TBL] [Abstract][Full Text] [Related]
39. [Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma].
Levy A; Guitera P; Kerob D; Ollivaud L; Archimbaud A; Dubertret L; Basset-Seguin N
Ann Dermatol Venereol; 2006 Feb; 133(2):157-60. PubMed ID: 16508601
[TBL] [Abstract][Full Text] [Related]
40. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
Thallinger C; Werzowa J; Poeppl W; Kovar FM; Pratscher B; Valent P; Quehenberger P; Joukhadar C
J Invest Dermatol; 2007 Oct; 127(10):2411-7. PubMed ID: 17508024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
